13F filer · CIK 1300336
Tekla Capital Management LLC
Boston, MA · filing since Q2 2013 · last filing Aug 10, 2023
Reported value
$2.6B
$-71.2M vs prior
Positions
166
New / sold out
9 / 20
Added / reduced
28 / 31
Turnover
7.2%
buys $186.3M · sells $284.9M
Top-10 weight
40.3%
Biggest buys vs Q1 2023
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | Merck & Co., Inc. | +176,032 | +31.9% | +$20.3M |
| Added | Amgen Inc. | +60,600 | +10.9% | +$13.5M |
| Added | Regeneron Pharmaceuticals, Inc. | +18,365 | +12.8% | +$13.2M |
| New | Insulet Corp. | +43,847 | – | +$12.6M |
| New | Tenet Healthcare Corp. | +149,070 | – | +$12.1M |
| Added | Baxter International, Inc. | +257,058 | +381.9% | +$11.7M |
| Added | IQVIA Holdings Inc. | +46,012 | +72.9% | +$10.3M |
| Added | Vaxcyte, Inc. | +189,232 | +3784.6% | +$9.5M |
| Added | Danaher Corp. | +37,123 | +35.1% | +$8.9M |
| New | Horizon Therapeutics plc | +72,425 | – | +$7.4M |
27 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2023
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | LLYEli Lilly and Company | -75,565 | -26.2% | $-35.4M |
| Reduced | The Cigna Group | -86,292 | -47.2% | $-24.2M |
| Reduced | Seagen Inc. | -112,332 | -50.0% | $-21.6M |
| Reduced | Bristol-Myers Squibb Company | -205,298 | -30.9% | $-13.1M |
| Reduced | Unitedhealth Group Inc. | -27,212 | -11.6% | $-13.1M |
| Reduced | Sarepta Therapeutics, Inc. | -106,216 | -37.2% | $-12.2M |
| Reduced | Intuitive Surgical, Inc. | -28,700 | -25.5% | $-9.8M |
| Sold out | Travere Therapeutics, Inc. | -418,520 | -100.0% | $-9.4M |
| Sold out | Laboratory Corporation of America Holdings | -40,042 | -100.0% | $-9.2M |
| Reduced | argenx SE | -22,757 | -25.8% | $-8.9M |
41 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2023
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Amgen Inc.COMMON | 616,539 | $136.9M | 5.36% |
| 2 | JNJJohnson & Johnson | 721,779 | $119.5M | 4.68% |
| 3 | Gilead Sciences, Inc.COMMON | 1,533,884 | $118.2M | 4.63% |
| 4 | Regeneron Pharmaceuticals, Inc.COMMON | 161,418 | $116.0M | 4.54% |
| 5 | Vertex Pharmaceuticals Inc.COMMON | 318,043 | $111.9M | 4.38% |
| 6 | LLYEli Lilly and Company | 213,352 | $100.1M | 3.92% |
| 7 | Unitedhealth Group Inc.COMMON | 206,961 | $99.5M | 3.89% |
| 8 | Merck & Co., Inc.COMMON | 728,154 | $84.0M | 3.29% |
| 9 | AbbVie Inc.COMMON | 545,629 | $73.5M | 2.88% |
| 10 | Biogen Inc.COMMON | 247,943 | $70.6M | 2.76% |
156 more rows. Subscribe for $29/month to see every row, download the data and use the API.